Viridian Therapeutics priced 11.4M-share offering at $22/sh for ~$251M gross proceeds

Viridian Therapeutics, Inc.\DE

Offering of 11,425,000 shares at $22.00/share; underwriters have 30-day option for up to 1,713,750 additional shares.
Gross proceeds of ~$251.35M before underwriting discounts and expenses; closing expected October 23, 2025.
Net proceeds combined with existing cash, $70M Kissei upfront (Q4 2025), $55M DRI payment, $115M potential DRI milestones, and $30M term loan to fund operations.
Company assumes revenue from veligrotug and VRDN-003 if approved on anticipated timelines to extend cash runway.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.